- Home
- HNRG vs PSNL Comparison
HNRG vs PSNL Comparison
Compare HNRG & PSNL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HNRG | PSNL |
|---|---|---|
| Founded | 1949 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Coal Mining | Medical Specialities |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 823.6M | 872.1M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | HNRG | PSNL |
|---|---|---|
| Price | $22.42 | $8.97 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 7 |
| Target Price | ★ $20.00 | $10.71 |
| AVG Volume (30 Days) | 507.3K | ★ 1.6M |
| Earning Date | 11-10-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $461,142,000.00 | $69,103,000.00 |
| Revenue This Year | $18.77 | N/A |
| Revenue Next Year | N/A | $20.33 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 7.15 | N/A |
| 52 Week Low | $8.37 | $2.83 |
| 52 Week High | $24.70 | $11.40 |
Technical Indicators
Market Signals| Indicator | HNRG | PSNL |
|---|---|---|
| Relative Strength Index (RSI) | 60.59 | 47.08 |
| Support Level | $19.02 | $9.34 |
| Resistance Level | $22.63 | $9.85 |
| Average True Range (ATR) | 0.88 | 0.70 |
| MACD | 0.32 | -0.15 |
| Stochastic Oscillator | 76.50 | 2.17 |
Price Performance
Historical ComparisonAbout HNRG Hallador Energy Company
Hallador Energy Co is a coal mining company with operations in Indiana, USA, and it is part of the electric power generation industry. The operations of the company are divided into two primary reportable segments, the Coal Operations and Electric Operations segments. The majority of revenue is earned from the Coal Operations segment.
About PSNL Personalis Inc.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.